drugset / Trial / NCT04253353

A Drug-Drug Interaction Study To Estimate The Effect Of Tafamidis On Rosuvastatin Pharmacokinetics

NCT04253353

Phase 1 Completed 12 enrolled Pfizer
NaSequentialOpen-labelBasic science

Summary

Each subject will be given a single oral dose of rosuvastatin on Day 1 in Period 1. In Period 2, after a washout period of at least 5 days, each subject will receive oral doses of tafamidis twice daily (BID) on days 1 and 2, followed by tafamidis once daily (QD) on days 3 to 9 with an oral dose of rosuvastatin on Day 7. Rosuvastatin exposures will be compared between Periods 1 and 2 to estimate the effect of tafamidis on rosuvastatin PK in healthy subjects.

Timeline

Start
2020-02-06
Primary completion
2020-08-10
Completion
2020-08-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule 10 mg Oral
Subject Tafamidis Unknown 61 mg Oral

Indications

No indication recorded.